881 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA http://www.zacks.com/stock/news/252113/merck-pfizers-diabetes-drug-accepted-for-review-by-fda-ema?cid=CS-ZC-FT-252113 Mar 08, 2017 - Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.
The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi http://www.zacks.com/stock/news/251714/the-zacks-analyst-blog-highlights-mylan-roche-astrazeneca-merck-and-sanofi?cid=CS-ZC-FT-251714 Mar 06, 2017 - The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi
5 FDA Decisions to Watch Out for in Mar 2017 http://www.zacks.com/stock/news/251688/5-fda-decisions-to-watch-out-for-in-mar-2017?cid=CS-ZC-FT-251688 Mar 06, 2017 - Companies like Merck (MRK) are awaiting key FDA decisions this month.
What's in Store for Immune Design (IMDZ) in Q4 Earnings? http://www.zacks.com/stock/news/251654/whats-in-store-for-immune-design-imdz-in-q4-earnings?cid=CS-ZC-FT-251654 Mar 03, 2017 - Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.
Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug http://www.zacks.com/stock/news/251551/pharma-stock-roundup-mylan-endo-report-4q-results-fda-nod-for-azn-diabetes-drug?cid=CS-ZC-FT-251551 Mar 03, 2017 - Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4 http://www.zacks.com/stock/news/251543/aduro-adro-loss-wider-than-expected-sales-miss-in-q4?cid=CS-ZC-FT-251543 Mar 03, 2017 - Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
M&As, Pipeline Catalysts to Drive Pharma Sector http://www.zacks.com/commentary/105123/mas-pipeline-catalysts-to-drive-pharma-sector?cid=CS-ZC--105123 Mar 01, 2017 - M&As, Pipeline Catalysts to Drive Pharma Sector
Pharma Industry Outlook - February/March 2017 http://www.zacks.com/commentary/104804/pharma-industry-outlook-february-march-2017?cid=CS-ZC--104804 Feb 27, 2017 - Pharma Industry Outlook - February/March 2017
Bristol-Myers Tanks, Buy These Two Large Cap Pharma Stocks Instead http://www.zacks.com/stock/news/227119/bristol-myers-tanks-buy-these-two-large-cap-pharma-stocks-instead?cid=CS-ZC-FT-227119 Aug 05, 2016 - As Bristol-Myers (BMY) tanks, check out these other large cap pharma stocks.
Shares of Bristol-Myers Falling After Failed Study, While Its Rival Is Surging http://www.zacks.com/stock/news/227117/shares-of-bristol-myers-falling-after-failed-study-while-its-rival-is-surging?cid=CS-ZC-FT-227117 Aug 05, 2016 - Shares of Bristol-Myers were falling in morning trade Friday after one of their drugs didn't reach the levels they were hoping for, while its rival Merck saw its shares climb as its competing drug was more successful in the same trial earlier this year.

Pages: 1...80818283848586878889

<<<Page 85>